从压力到预后:为晚期慢性肝病中的门脉高压建立共同语言
该文指出代偿期晚期慢性肝病传统以CSPH(HVPG≥10 mmHg)分层,CSPH者4年失代偿风险29% vs 无CSPH者10%。非侵入性检测(NIT)如弹性成像、ANTICIPATE等模型可直接预测失代偿,预后准确性堪比HVPG,但需标准化临床终点并采用基于结局的术语。
要点
- CSPH(HVPG≥10 mmHg)是预后不良标志,4年失代偿风险29% vs 10%。
- NIT模型预测失代偿准确性堪比HVPG,可纵向动态评估风险。
- 推广NIT直接预测需标准化临床终点,聚焦门脉高压相关失代偿事件。
核心结论
- 应从静态血流动力学阈值转向基于NIT的动态个体化风险预测,并以标准化结局术语沟通预后。
研究设计与样本
- 原文为综述/立场文章,未报告系统检索范围与样本量。
主要发现
- CSPH者4年失代偿风险为29%,无CSPH者为10%。
- 弹性成像、ANTICIPATE、Non-Invasive CSPH Estimated Risk及Portal Hypertension Decompensation Score等NIT工具预测失代偿的预后准确性堪比HVPG测量。
- 常规使用NIT可对患者风险及对疾病修饰治疗的反应进行连续纵向再评估。
关键数值与推荐
- CSPH定义为HVPG≥10 mm Hg。
- NIT直接预测模型临床推广需标准化临床终点,聚焦经典门脉高压相关失代偿事件而非异质性复合结局。
临床怎么用
- 可用NIT工具替代HVPG进行失代偿风险的动态个体化评估,并统一采用门脉高压相关失代偿事件作为临床终点。
局限性
- 原文未报告综述的检索范围、纳入标准及证据等级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification in compensated advanced chronic liver disease has traditionally been based on the identification of clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) of ≥10 mm Hg. CSPH is a well-established marker of poor prognosis, associated with a substantially higher risk of decompensation compared with the absence of CSPH (29% vs 10% at 4 years).Non-invasive tests (NITs) are increasingly used as surrogates for CSPH, yet their potential to directly predict clinical endpoints of decompensation or liver-related death remains underutilised. There is a clinical need to transition from static haemodynamic thresholds to the dynamic, individualised prediction of clinically meaningful outcomes using NIT-based direct risk assessment. Tools such as elastography, models such as ANTICIPATE and Non-Invasive CSPH Estimated Risk, and purely blood-based scores such as the Portal Hypertension Decompensation Score demonstrate prognostic accuracy comparable to HVPG measurement for the prediction of decompensation. The routine use of NITs also allows for continuous, longitudinal reassessment of a patient's risk and response to disease-modifying treatment.For these direct prediction models to be widely adopted in clinical practice, standardisation of clinical endpoints is essential, focusing on classical portal hypertension-related decompensation events rather than heterogeneous composite outcomes. Adopting an outcome-based terminology rather than relying on surrogate markers may also enhance public awareness, convey disease severity more effectively and foster earlier interventions for patients at risk.
引用
- Jeffrey AW, Tsochatzis EA, Genescà J, et al. From pressure to prognosis: establishing a common language for portal hypertension in advanced chronic liver disease. Gut. 2026. PMID: 42642217. doi:10.1136/gutjnl-2026-339845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。